-
Vietnam, South Korea sign deals on tech, nuclear power
-
EU nears approval of Ukraine loan after Hungary pipeline row
-
Duterte jurisdiction appeal quashed at ICC
-
Three ships targeted in Hormuz, Iran seizes two: monitors, Guards
-
Iran murals project defiance in war with US
-
Oil prices rise despite US-Iran ceasefire extension
-
Ships attacked in Gulf as Trump extends Iran ceasefire
-
Germany set to slash growth forecast due to Mideast war
-
Pakistan's capital holds its breath with US-Iran talks in limbo
-
Groundbreaking Iranian snooker star Vafaei takes on the world
-
Sakib Hussain: IPL quick whose mum sold her jewellery to fund cricket dream
-
US-based Buddhist monks bring peace walk to Sri Lanka
-
NASA unveils new space telescope to give 'atlas of the universe'
-
Trump extends ceasefire, claims Iran 'collapsing financially'
-
The tiny, defiant Nile island caught in the heart of Sudan's war
-
UK inflation jumps as Mideast war propels energy prices
-
Oil, stocks mixed as traders weigh outlook after Trump extends truce
-
Anthropic probes unauthorized access to Mythos AI model
-
Stadium that was symbol of NZ post-quake rebuild to hold first match
-
Blazers stun Spurs after Wemby injury, Lakers down Rockets
-
Chinese carmakers aim to build up presence in Europe
-
Maoist landmine legacy haunts India
-
Fiji villagers reject plan for 'Pacific ashtray' in beach paradise
-
India orders school water bells to beat heat
-
Japanese minnows one win from fairytale Champions League title
-
Rugby Australia eyes brighter future as Lions tour brings cash windfall
-
Blazers rally stuns Spurs after Wembanyama injury
-
Young Chinese use AI to launch one-person firms over job anxiety
-
Delicate extraction: Malaysia offers rare earths alternative to China
-
Oil, stocks fall as traders weigh outlook after Trump extends truce
-
Pope to visit prison on final leg of Africa tour
-
US military says key weapons system staying in South Korea
-
India strangles final Maoist bastion as mining looms
-
AI-powered robots offer new hope to German factories
-
Indonesia orangutan forest cleared for 'carbon-neutral' packaging firm
-
PGA Tour mulls pathway back for golfers as LIV plots survival
-
One month phone-free: Young Americans try digital detox
-
Questions about Tesla spending binge ahead of earnings
-
Rome summons Russian ambassador over insults against Meloni
-
US tells Afghans to choose Taliban home or DR Congo: activist
-
John Ternus to lead Apple in the age of AI
-
SpaceX partners with AI startup Cursor, may buy it for $60 bn
-
Mexico pyramid shooter inspired by Columbine attack, pre-Hispanic sacrifices
-
Mexico pyramid shooter planned attack, fixated on US massacre
-
Mbappe on the mark as Real Madrid sink Alaves
-
Rosenior blasts Chelsea flops after 'unacceptable' Brighton defeat
-
Inter roar back to beat Como and reach Italian Cup final
-
Lens sweep past Toulouse to reach French Cup final
-
Brighton crush Chelsea to pile pressure on under-fire Rosenior
-
Strait of Hormuz blockade drives up costs at Panama Canal
The scientist rewriting DNA, and the future of medicine
A revolution is underway in gene editing -- and at its forefront is David Liu, an American molecular biologist whose pioneering work is rewriting the building blocks of life with unprecedented precision.
A professor at the Broad Institute of MIT and Harvard, Liu was awarded a Breakthrough Prize in Life Sciences on Saturday for developing two transformative technologies: one already improving the lives of patients with severe genetic diseases, the other poised to reshape medicine in the years ahead.
He spoke with AFP ahead of the Los Angeles ceremony for the prestigious Silicon Valley-founded award.
He will receive $3 million for his work on "base editing" and "prime editing," and plans to donate most of it to support his charitable foundation.
"The ability to change a DNA sequence of our choosing into a new sequence of our choosing is a fundamentally very powerful capability," the 51-year-old said, foreseeing uses not just in human medicine but areas like developing more nutritious or disease-resistant crops.
- Correcting the code -
DNA is made up of four chemical "letters" -- the nucleotide bases A, G, T and C. Mutations in this sequence cause thousands of human diseases, yet until recently, gene editing could only fix a limited number of them.
Even CRISPR-Cas9, the groundbreaking technology that earned a Nobel Prize in 2020, has major limitations.
It cuts both strands of the DNA helix, making it most useful to disrupt rather than correct genes, while the process can introduce new errors.
"Being able to use genome editing to treat genetic diseases requires, in most cases, ways to correct a DNA misspelling, not simply to disrupt a gene," Liu said.
That insight led his lab to develop base editing, which uses the Cas9 protein -- disabled so it can no longer cut both DNA strands -- to find a target DNA sequence and another enzyme to convert one letter to another -- for example, C to T or G to A.
Reversing the change -- from T to C or A to G -- was tougher. Liu's team overcame the challenge by engineering entirely new enzymes.
These base editors can now correct about 30 percent of the mutations that cause genetic diseases. The technology is already in at least 14 clinical trials.
In one of them, Beam Therapeutics -- which Liu co-founded -- announced it had treated patients of AATD, a rare genetic disorder affecting the lungs and liver, with a single drug infusion.
While traditional gene therapies often disrupt faulty genes or work around them, base editing repairs the mutation itself.
"This was the first time that humans have corrected a mutation that causes a genetic disease in a patient," Liu said.
- Cystic fibrosis hope -
Base editing, quickly dubbed "CRISPR 2.0," can't fix every mutation.
About 70 percent of the roughly 100,000 known disease-causing mutations remain out of its reach, including those caused by missing or extra letters.
To expand the toolkit, Liu's lab introduced prime editing in 2019 -- a method capable of replacing entire sections of faulty DNA with corrected sequences.
If CRISPR is like scissors that cut DNA, and base editors are like using a pencil to correct individual letters, then prime editing is the equivalent of a word processor's "find and replace" function.
Creating this tool required a series of breakthroughs Liu's team describes as "small miracles." The result is, he said, "the most versatile way we know of to edit the human genome."
Among the targets Liu and his team have already pursued with prime editing: cystic fibrosis, a common genetic disease usually caused by three missing DNA letters that causes thick mucus buildup in the lungs and digestive system.
Liu's lab has made much of its work freely accessible, sharing DNA blueprints through a nonprofit library used by tens of thousands of labs worldwide.
"The science we create -- which is ultimately funded by society, through governments and donors -- ultimately goes back to benefit society."
This year's Breakthrough Prize awards come at a fraught moment for US science, as President Donald Trump's government strips funding for institutions like the National Institutes of Health (NIH).
"The NIH is a treasure, not just for this country but for the world," said Liu. "Trying to dismantle the heart of what supports science in this country is like burning your seed corn."
P.Staeheli--VB